Aktis Oncology, Inc.
AKTS
$25.00
$0.281.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | 111.37% | 123.01% | 100.43% | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 111.37% | 123.01% | 100.43% | ||
| Cost of Revenue | 35.71% | 26.31% | 30.83% | ||
| Gross Profit | -28.60% | -16.60% | -25.27% | ||
| SG&A Expenses | 77.92% | 58.22% | -30.54% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 43.07% | 32.38% | 16.16% | ||
| Operating Income | -37.86% | -25.15% | -11.13% | ||
| Income Before Tax | -33.58% | -22.29% | -25.56% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -33.58% | -22.29% | -25.56% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -33.58% | -22.29% | -25.56% | ||
| EBIT | -37.86% | -25.15% | -11.13% | ||
| EBITDA | -37.28% | -24.89% | -9.78% | ||
| EPS Basic | 98.05% | 97.97% | -13.41% | ||
| Normalized Basic EPS | 98.05% | 97.97% | -13.41% | ||
| EPS Diluted | 98.05% | 97.97% | -13.41% | ||
| Normalized Diluted EPS | 98.05% | 97.97% | -13.41% | ||
| Average Basic Shares Outstanding | 6,750.01% | 5,935.00% | 10.72% | ||
| Average Diluted Shares Outstanding | 6,750.01% | 5,935.00% | 10.72% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||